
Weight loss jab Mounjaro linked to lower dementia risk
People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found.
The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity.
Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. https://t.co/WhHodrztS1 pic.twitter.com/Rll5Eg3ycU — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025
Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic.
GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed.
The other half used other anti-diabetic medication.
📢Important update
Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025.
✅Around 1,000 people in Dorset will qualify under strict national criteria
✅No need to contact your doctor
More: https://t.co/ml4QJgZ224 pic.twitter.com/uURpuIuYzx — NHS Dorset (@NHSDorset) June 23, 2025
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke.
They were also 30% less likely to die during the follow-up period.
And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
Recommended reading:
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Recommended reading:
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia.
'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
21 minutes ago
- Daily Mail
Mounjaro users panic about going 'cold turkey' - as pharmacists warn slimming jab stocks could run out
People currently taking weight loss jabs have raised their concerns about going 'cold turkey'—amid pharmacists' warning of potential shortages. The National Pharmacy Association (NPA), which represents more than 6,000 independent community pharmacies says that the current booming demand for the medication, which includes Mounjaro and Wegovy, may become unsustainable. Their warning came after a recent poll of over 2,000 people showed an increasing demand for private and NHS -backed weight loss services. GPs in the UK are now allowed to prescribe the drugs, collectively known as GLP-1s, for the first time in a bid to tackle the nation's obesity crisis. An estimated 1.5 million people are now using weight loss jabs through the NHS or private clinics, while millions more are eligible. The recent NDA poll revealed a fifth of participants had attempted to access weight loss treatments in the last year. This figure rose to 35 per cent for those aged between 16 and 34, compared to only seven per cent of those over 55. In their warning, NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate from those who want it. 'It's clear from polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' They fear spiralling demand, fuelled partly by social media, could see people resort to unregulated online suppliers. These online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. The NPA is also calling for new regulations to protect patients buying weight loss medication online. They would like a full two-way consultation and a review of relevant historical medical records to be required before treatment is prescribed. Chatter amongst the jabbing community often leads to talk about coming off the drug, either willingly or because they can no longer access them. On Reddit, users have warned against stopping weight loss jabs suddenly, and rapid weight gain is always their primary concern—or warning. In one post, a woman planning to come off of Mounjaro asked for advice from anyone who had gone 'cold turkey'. The post, which was published at the beginning of July, quickly gained traction, with over 152 comments. In one, a user warned: 'Not just on my experience with MJ but other meds as well. It is a shock to the system to go cold turkey.' Another wrote: 'I stopped medicating for a vacation and gained 10lbs when I got back as MJ's half-life faded. Not fun going through weeks of medication and hard work to get back down. 'Restarting was bad because you need to re-acclimate your body to the medication which causes delay for a month too.' A third user added: 'I went cold turkey (came off for health reasons) after convincing myself I'd be fine, and hunger came back within a couple of weeks.' Meanwhile, a fourth user said: 'I haven't been able to afford it for the last two months and I voluntarily went cold turkey. Immediately gained 10lbs in the first month.' There is no evidence that stopping Mounjaro causes withdrawal symptoms in the traditional sense, says Kiran Jones, a clinical pharmacist at Oxford Online Pharmacy. But speaking to MailOnline, she explained: 'What people experience is a return to their underlying appetite regulation issues. 'These aren't withdrawal effects from the medicine itself, but rather a resurfacing of the body's natural behaviour without the GLP-1 support.' She continued: 'These medicines are generally intended for long-term use. For many people, that may mean continued use for life. 'The evidence shows that stopping treatment leads to weight regain for most people, often reversing much of the improved health progress they've made. 'It's important to say that no healthcare provider should recommend stopping Mounjaro simply because someone has reached a certain weight.' On those who may stop due to costs or concerns around supply, she said: 'Unfortunately, we don't yet have enough evidence to say what the best or safest approach to stopping looks like.' But, she added: 'Some people try gradually reducing the dose, extending time between injections, or staying on a lower maintenance dose for a set period before stopping altogether.' However, she warned: 'These approaches are based on anecdotal practice, not clinical data, and we can't recommend any one method over another.' The pharmacist also urged those stopping to speak to their providers about their policy on restarting, because, for example, she said: 'If your weight begins to creep up again, but your BMI doesn't reach 30, will they still offer treatment?' Last week, TikTok user @freyatheblondieee went viral after sharing a brutally honest video about suddenly stopping taking Mounjaro. 'Take this as a sign to NEVER go cold turkey from Mounjaro,' wrote the British content creator, while eating a burger. 'I would have done very sinister things for this burger. My hunger is out of control—I want to punch everyone who is not food in the face,' she added.


Scottish Sun
3 hours ago
- Scottish Sun
The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom
But health officials warn fat jabs are not a silver bullet and can come with some serious side effects WEIGHT UP The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs do often sound like a magical quick fix to overeating and demanding hunger pangs. But the drugs can leave some users feeling seriously unwell and many in hospital. Sign up for Scottish Sun newsletter Sign up 2 Monitoring Facebook posts could be a useful way to spot side effects that might be unknown, scientists say (Credit: Getty) After scouring social media, scientists have found the most common side effects of the popular fat-busting meds. Vomiting, nausea and headaches are the most talked-about side effects of the jabs, according to the new study, which analysed thousands of Facebook posts. The US researchers looked at how people in the US were discussing GLP-1 drugs like Wegovy, Ozempic, and Mounjaro on public pages. They found that gut issues were the most frequently mentioned side effects overall, especially among users of semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Mounjaro). Mental health concerns like anxiety and depression were also raised, but far less frequently. The study, published in JMIR Infodemiology, found that vomiting was most often mentioned in posts about Mounjaro, at 3.8 per cent. Meanwhile, Wegovy users mentioned depression more than any other group, with 1.57 per cent of posts referencing the symptom. The drugs, originally developed for type 2 diabetes, have soared in popularity thanks to their dramatic weight-loss effects, with celebs like Oprah Winfrey and Sharon Osbourne singing their praises. But they've also been linked to less glamorous side effects, such as joint pain, fatigue, hair loss, and in some cases, gallbladder problems. Despite the risks, experts say the drugs are still safe and effective for most patients. Weight Loss Jabs - Pros vs Cons They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. In the US, this number is even higher, with over 2 per cent of the population, approximately 4 million people, currently using these medications for weight loss. But health officials warn they are not a silver bullet and can come with side effects. The scientists found these effects varied by brand. Zepbound, a newer tirzepatide drug which is approved in the US but not the UK, was linked more often to high blood pressure, While Ozempic posts mentioned gallbladder issues most. Ozempic is approved for weight loss in the US but is only approved for diabetes in the UK. Scientists from the University of Maryland, who are behind the study, analysed nearly 60,000 unique public Facebook posts uploaded by US users of the medicines between 2022 and 2024, They used cluster analysis to map out which symptoms were often mentioned together. They found that vomiting, nausea and pancreatitis - a condition where the pancreas becomes inflamed - often came hand in hand, while anxiety frequently appeared alongside depression and fatigue. Posts about side effects spiked after major events including the US Food and Drug Administration approving Wegovy for teens, celebrity endorsements, and wider insurance coverage in the US. 2 Despite these increases, the proportion of people talking about side effects actually dropped over time. Scientists say monitoring social media could be a useful way to spot side effects that might be missed or underreported in clinical trials. But they warned that Facebook posts don't tell the full story as symptoms were self-reported, which means they can be exaggerated or incomplete. There is also no way to verify dosage, how long people were on the drugs, or even whether they were using genuine products.


The Sun
3 hours ago
- The Sun
The most common side effects of different fat jabs revealed – as researchers find vomiting and nausea top symptom
FAT jabs do often sound like a magical quick fix to overeating and demanding hunger pangs. But the drugs can leave some users feeling seriously unwell and many in hospital. 2 After scouring social media, scientists have found the most common side effects of the popular fat-busting meds. Vomiting, nausea and headaches are the most talked-about side effects of the jabs, according to the new study, which analysed thousands of Facebook posts. The US researchers looked at how people in the US were discussing GLP-1 drugs like Wegovy, Ozempic, and Mounjaro on public pages. They found that gut issues were the most frequently mentioned side effects overall, especially among users of semaglutide (the active ingredient in Wegovy) and tirzepatide (the active ingredient in Mounjaro). Mental health concerns like anxiety and depression were also raised, but far less frequently. The study, published in JMIR Infodemiology, found that vomiting was most often mentioned in posts about Mounjaro, a drug containing tirzepatide, at 3.8 per cent. Meanwhile, Wegovy users mentioned depression more than any other group, with 1.57 per cent of posts referencing the symptom. The drugs, originally developed for type 2 diabetes, have soared in popularity thanks to their dramatic weight-loss effects, with celebs like Oprah Winfrey and Sharon Osbourne singing their praises. But they've also been linked to less glamorous side effects, such as joint pain, fatigue, hair loss, and in some cases, gallbladder problems. Despite the risks, experts say the drugs are still safe and effective for most patients. Weight Loss Jabs - Pros vs Cons They help control blood sugar, trigger rapid weight loss, and cut the risk of dying from heart disease by around a fifth in people with obesity or type 2 diabetes. Roughly 1.5million people in the UK are now taking GLP-1 drugs, which have been hailed by some as game-changers in the fight against obesity. In the US, this number is even higher, with over 2 per cent of the population, approximately 4 million people, currently using these medications for weight loss. But health officials warn they are not a silver bullet and can come with side effects. The scientists found these effects varied by brand. Zepbound, a newer tirzepatide drug which is approved in the US but not the UK, was linked more often to high blood pressure, While Ozempic posts mentioned gallbladder issues most. Ozempic is approved for weight loss in the US but is only approved for diabetes in the UK. Scientists from the University of Maryland, who are behind the study, analysed nearly 60,000 unique public Facebook posts uploaded by US users of the medicines between 2022 and 2024, They used cluster analysis to map out which symptoms were often mentioned together. They found that vomiting, nausea and pancreatitis - a condition where the pancreas becomes inflamed - often came hand in hand, while anxiety frequently appeared alongside depression and fatigue. Posts about side effects spiked after major events including the US Food and Drug Administration approving Wegovy for teens, celebrity endorsements, and wider insurance coverage in the US. 2 Despite these increases, the proportion of people talking about side effects actually dropped over time. Scientists say monitoring social media could be a useful way to spot side effects that might be missed or underreported in clinical trials. But they warned that Facebook posts don't tell the full story as symptoms were self-reported, which means they can be exaggerated or incomplete. There is also no way to verify dosage, how long people were on the drugs, or even whether they were using genuine products. However, the findings offer insight into what real-world users are experiencing, beyond the controlled world of clinical trials. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.